| INTRODUCTION
Tumor necrosis factor-α (TNF) elicits a wide range of responses in almost all cell types, including cell death, survival, differentiation, and proliferation. 1 TNF binds to either of two cell surface receptors; TNFR1 and TNFR2, which mediate distinct signaling pathways. [2] [3] [4] The cell surface expression of each receptor is highly and independently regulated, and may determine the dominant response. TNFR1 can promote cell death, 2 while TNFR2
can activate a pathway involving endothelial/epithelial nonreceptor tyrosine kinase (Etk), implicated in cell adhesion, migration, proliferation, and survival. 4 TNFR2-mediated activation of Etk in endothelial cells or renal cell carcinoma cells (RCC) results in tyrosine phosphorylation within the cytoplasmic sequences of vascular endothelial growth factor receptor-2 (VEGFR2), resulting in a VEGFindependent VEGFR2-mediated response involving activation of a PI-3K and Akt. 3, 5 TNFR2 may also localize to mitochondria, 6 but its function within this organelle is unknown.
Emerging evidence has shown that the capacity of some tumors to grow and propagate resides in a small population of slowly proliferating tumor cells referred to as cancer stem cells (CSCs). 7 CSCs possess the characteristics of self-renewal and are resistant to chemotherapy and radiotherapy. As they persist after cytotoxic treatment, they can give rise through cell division and differentiation to tumor cell progeny and tumor recurrence. 7 Based on these CSCs properties, it has been proposed that their elimination can halt neoplastic expansion. 8 CD133, alone or in combination with other molecular markers, has been used to isolate stem cells from normal kidney and CSCs from RCC. 9 We refer to the CD133 + CSCs in our study as "cancer stem-like cells" because although previous studies have reported that CD133 + cells from several human tumors exhibit xenotransplantation potential in severe combined immunodeficiency (SCID) mice, 10, 11 isolated CD133 + cells from human RCC tissue failed to form tumors when transplanted into SCID mice but instead, these cells potentiate tumor engraftment when cotransplanted with CD133 -RCC cells. 11 Based on these data, we are uncertain if they are truly cancer stem cells capable of differentiation into more mature RCC cells even though they express stem cell markers. Significantly, CD133 expression has been suggested as a useful risk stratification tool in RCC. 12 Signal transducers and activators of transcription (STAT) exist as latent, un-phosphorylated monomers in the cytoplasm, and transmit signals from diverse cytokines and growth factors. 13 STAT proteins can be tyrosine, serine, and/or threonine phosphorylated. 14 The best-known pathway involves the Janus kinase (JAK)-mediated phosphorylation of tyrosine residues, inducing STAT dimerization and translocation into the nucleus where phosphorylated (p)STATs act as transcription factors. 15 For STAT3, JAK signaling is typically activated in response to cytokines that bind to receptors containing gp130, inducing the JAK-mediated phosphorylation of tyrosine-705. 15 Nuclear phosphorylation of STAT3 tyrosine-Y705 (pSTAT3 Ty705 ) promotes cell growth and many malignancies exhibit constitutive pSTAT3 Ty705 . Neither TNF receptor has been linked to this response. Recent evidence has shown that phosphorylation of STAT3 on serine-727 (pSTAT3 Ser727 ) also contributes to, or is sufficient for, the growth and transformation of malignant cells. 16, 17 pSTAT3 Ser727 has been identified in mitochondria, [16] [17] [18] and pSTAT3 Ser727 but not pSTAT3 Ty705 is crucial for the optimal activity of complexes of the electron transport chain (ETC) in mitochondria where it protects cells against the stress-induced generation of reactive oxygen species (ROS). 19, 20 We recently reported that selective ligation of TNFR2 can drive the cell-cycle entry of CD133 + CSCs isolated from ccRCC (ccRCC-CD133+ CSCs), rendering them sensitive to killing by a chemotherapeutic agent. 21 The current investigation was initiated to understand the mechanism through which TNFR2 acts. We describe an unexpected link between TNFR2 and STAT3 signaling in ccRCCCSCs that express CD133 and other stem cell markers. We report that in CD133 + CSCs, TNFR2 signaling through the VEGFR2/Phosphoinositide 3-kinase (PI-3K)/Protein kinase-B (Akt)/Mechanistic Target of Rapamycin complex (mTORC) pathway induces pSTAT3 Ser727 that colocalizes with TNFR2 in mitochondria. Disruption of this pathway results in mitochondrial instability, mitochondrial outer membrane permeabilization, generation of ROS, and necroptotic cell death.
| MATERIALS AND METHODS

| Reagents/Antibodies
Antibodies and reagents used were anti-CD133/ and N-Acetyl-L-Cysteine (NAC, cat~ab143032), and phosphorylated JAK-1, −2, and −3 (cat~ab32101, ab61102; ab138005; Abcam). Rabbit anti-human mitochondria (MAB3598) (Millipore Ltd 
| Immunofluorescence (IF) and confocal laser scanning microscopy (CLSM)
Immunostaining was carried out as previously described. 21 For organ cultures, deparaffinized sections were exposed to high-pressure antigen retrieval before incubation with antipSTAT3 Ser727 , -CD133 or -TNFR2 (1:100) overnight (4°C).
For cells, 8-well slide chambers were permeabilized at −20°C in cold methanol (4 minutes) before incubation with anti-CD133 alone or -anti-SSAE and -Nanog (1:100 dilution) overnight (4°C 
| Mitochondria Isolation
ccRCC-CD133+ CSCs (1.5 × 10 6 cells) were treated with R2TNF (1 μg/mL) or left UT for 30 minutes (37°C) then mitochondrial fraction was isolated using Mitochondria Isolation Kit (cat~89874; Thermofisher Scientific). As we have previously described, 31 for immunogold electron microscopy (IGEM), cells were cells stained for TNFR2 and pSTAT3 Ser727 (1:5) overnight and further stained with 20 and 5nm gold particles (British Biocell, Cardiff, UK) (1:100), followed by 2% phosphotungstic acid pH 7.0 (30 seconds) before viewing on TEM. As we were unable to obtain sufficient mitochondria fraction for immunoblotting from ccRCC-CD133+ CSCs, we used a human RCC immortalized cell line (RCC-26; derived from a patient with stage I disease) 32 Equal amount of protein (50µg) from mitochondria and cytosolic fraction were probed with anti-TNFR2, -total STAT3 or -pSTAT3 Ser727 followed by specific HRP-conjugated secondary antibodies prior to visualization. 
| Measurement of intracellular ROS
| Statistical analysis
Data are expressed as mean ± SEM To account for patientspecific differences, all experiments were performed with organ cultures and corresponding isolated cells from at least three patients with triplicate samples in each assay unless otherwise stated. Differences between two groups were analyzed by Student's t test and between >2 groups by one or two-way analysis of variance followed by Bonferroni's post hoc test using GraphPad Prism v7.0 (San Diego). A P value <.05 was considered statistically significant.
| RESULTS
| TNFR2 ligation induces pSTAT3
Ser727 but not pSTAT3
Ty705 in CD133 + cells of ccRCC in situ in organ culture and in isolated cells To further study the effect of TNF, we isolated CD133 + cells from ccRCC-(ccRCC CD133+ CSCs). 21 Isolated cells were strongly positive for CD133 and exhibited a stem-cell phenotype evidenced by strong immunostaining for SSEA-4 and Nanog ( Figure 1E ,F), as previously reported. 21 To test whether TNF phosphorylates STAT3 
| TNFR2-induced pSTAT3
Ser727 is dependent upon a VEGFR2/PI-3K/Akt/ mTORC kinase cascade in ccRCC-
CD133+
CSCs
Our previous studies 3 revealed that an important step in the TNFR2 signaling pathway in ccRCC linked to cellcycle entry involves cross-talk between phosphorylation of VEGFR2 at tyrosine-1059 (pVEGFR2 Y1059 ) and cytosolic protein tyrosine kinase Etk. Phosphorylated VEGFR2 then initiates a signaling cascade leading to the activation of Akt. In other cell types where this pathway has been This activates the PI-3K p85 catalytic subunit, which phosphorylates phosphatidylinositol 4,5 bis-phosphate (PIP2) to form phosphatidylinositol 3,4,5 tris-phosphate (PIP3) in the inner leaflet of the plasma membrane. Figure 3A-D) . To determine the relevance of this pathway for TNFR2-mediated pSTAT3 Ser727 signaling, cells were pretreated with specific inhibitors to these kinases--SU5408, BMK120, AZ5363 or Ku0063794 (VEGFR2, PI-3K, Akt, and mTOR, respectively) and each decreased R2TNF-induced pSTAT3 Ser727 formation by ~4-fold in ccRCC-CD133+ CSCs ( Figure 4A , quantified in B).
These data indicate a role for the ETK/VEGFR2/PI-3K/ Akt/mTORC pathway in TNFR2-mediated pSTAT3 Ser727 in ccRCC-CD133+ CSCs.
| Inhibition of VEGFR2/PI-3K/Akt/ mTORC pathway induced cell death in ccRCC-
CD133+ CSCs
To confirm the involvement of the VEGFR2/PI-3K/Akt/ mTORC pathway in TNFR2-mediated pSTAT3 Ser727 in ccRCC-
CD133+
CSCs, we assessed the effect of specific inhibitors to these kinases either alone or in combination with wtTNF, R1TNF or R2TNF. Cells were either left UT or pretreated with the inhibitors alone for 1h or with inhibitors prior to TNF treatment for 30min (37°C) and subjected (Table 1 ). In the absence of inhibitors, R2TNF also induced cell death, but to a significantly lesser extent than wtTNF or R1TNF as previously reported. 4 Each of the kinase inhibitors alone also induced cell death and this was only slightly increased by the addition of wtTNF, R1TNF or R2TNF. These data further suggest that the VEGFR2/PI-3K/Akt/mTORC pathway may protect from cell death. . In comparison to UT controls, which showed a rare signal, R2TNF induced a marked signal for TNFR2 or pSTAT3
| wtTNF and
Ser727 expression in mitochondria in ccRCC-
CD133+
CSCs ( Figure 4C ), also detected by IGEM ( Figure 4D ). As we were unable to obtain a sufficient number of ccRCC-
CSCs for immunoblotting isolated mitochondria, we isolated mitochondria from a ccRCC immortalized cell line (RCC-26) treated with R2TNF or left UT and observed that R2TNF induced the expression of TNFR2 and pSTAT3 Ser727 ( Figure 4E ). These data suggest that R2TNF mediates increased expression and translocation of both TNFR2 and pSTAT3 Ser727 to mitochondria in ccRCC- Figure S1B ). TBED showed similar findings (data not shown). We wondered if death in these circumstances was mediated by unopposed autocrine/paracrine TNF signaling via TNFR1. To address the role of TNFR1 more directly, cells were transfected with siRNA targeting TNFR1 39 at the same time as siRNA targeting TNFR2 and/or STAT3 for 48 hours, followed by treatment with wtTNF for 30 minutes (37°C). Immunoblot analysis demonstrated low levels of TNFR1 expression in control groups (UT and NTsiRNA), which was slightly induced by wtTNF than further diminished by TNFR1siRNA ( Figure  S1C) . Unexpectedly, the absence of TNFR1 signals induced some degree of cell death (detected by TUNEL) (quantified in Figure 5A ) but significantly less than that induced by the absence of TNFR2 or STAT3 signals either alone ( ¥ P < .0001) or in combination ( φ P < 0.001). The absence of all three signals induced an even higher level of cell death ( ✤ P < .01).
Some protection was conferred with the knockdown expression of TNFR1 in the absence of either TNFR2 or STAT3 signals alone ( x P < 0.0001) but not in combination ( Ψ P < .001). The degree of cell death induced by the absence of TNFR1, TNFR2, and STAT3 either alone or in combination compared to control groups is illustrated in phase contrast micrographs ( Figure S1D ). Collectively, these data indicate that cell death induced by the absence of TNFR2 and of STAT3 signals are largely independent of TNFR1 signals.
| Mitochondria promote cell death induced by the absence of TNFR2 and of STAT3 signals in ccRCC-
CD133+
CSCs
Since TNFR2 signaling causes both TNFR2 and pSTAT-3
Ser727 to localize to mitochondria in ccRCC-CD133+ CSCs, we
F I G U R E 5 (A) Isolates of ccRCC-
CD133+
CSCs were transfected with siRNAtargeting TNFR1 for 24h or TNFR2 or STAT3 for 72 h at 37°C or with control siRNA (nontargeting siRNA-NTsiRNA or left untreated-UT-in media alone) shows increased cell death (presented as percentage of TUNEL-positive cell/total cells (×100) at ×40 Mag) in the absence of all three proteins, more pronounced in the absence of TNFR2 or STAT3 signals as compared to absence of TNFR1 or control group. Notably, the absence of TNFR1 signals in combination with the absence of TNFR2 or STAT3 signals confer protection by a small margin. Error bars represent mean ± SEM; ** P < .01 or *** P < .001-vs control group, ¥ P < .0001-vs TNFR1siRNA; examined if mitochondria played a role in cell death when these signals were disrupted. We first evaluated the effect of TNFR2 and STAT3 knockdown expression on mitochondrial morphology using TEM of mitochondrial fractions. In comparison to the control groups, the absence of TNFR2/ STAT3 signals induced noticeable changes in mitochondrial morphology with loss of cristae and a discontinuous outer membrane ( Figure 5B ). Mitochondria promote cell death through two general mechanisms, which may not be mutually exclusive. The first involves the loss of mitochondrial outer membrane integrity resulting in the escape of certain mitochondrial proteins into the cytosol. The other is mediated by pathological increases in ROS generation through dysregulation of the mitochondrial ETC. 40, 41 Excessive ROS production may lead to apoptosis or necroptosis. We used surrogate assays to detect these events. To determine the loss of mitochondrial outer membrane integrity, we assessed the cytochrome c release following the knockdown expression of TNFR2 or STAT3 in ccRCC-CD133+ CSCs. Cells were incubated with MitoTracker™Red for 15 minutes (37°C) and immunostained using anti-cytochrome c. In comparison to control groups (UT and NTsiRNA), which showed a strong punctate staining of cytochrome c in mitochondria, the absence of TNFR2/STAT3 signals resulted in a diffuse intense signal in the cytoplasm ( Figure 5C ). These data indicate that mitochondrial release of proteins into the cytosol may contribute to cell death induced by the absence of TNFR2/ STAT3 signals. We were unable to perform subcellular fractionation for the detection of cytochrome c following siRNA transfection of ccRCC-CD133+ CSCs due to insufficient cell number. Next, we evaluated changes in cellular ROS levels using the oxidative stress-sensitive dye CellROX Green by flow cytometry and IF-confocal microscopy. Flow cytometry showed a strong signal in the absence of TNFR2/STAT3 signals compared to control groups, significantly diminished by ROS scavenger NAC ( Figure 5D ). IF-confocal microscopy demonstrated a marked signal in cells with fragmented nuclei and distorted outer membrane, significantly less with NAC pretreatment by ~7-fold in the absence of TNFR2 signals and by ~5-fold in the absence of STAT3 signals as compared to the control group ( Figure 5E ). The addition of wtTNF did not induce any significant changes.
| TNFR2/STAT3 signals protect ccRCC-
CD133+
CSCs from cell death mediated predominantly through a caspase-independent necroptotic pathway To determine the cell death mechanism induced by the absence of TNFR2/STAT3 signals, we assessed the number of cells containing cleaved caspase 3 (a marker of apoptotic cell death) and serine- either alone or in combination, or prior to siRNA targeting TNFR2 and STAT3 (±wtTNF) and cell death quantified by TUNEL. zVAD.fmk conferred partial protection ~2-fold from cell death induced by the absence of TNFR2/STAT3 signals, more attenuated by Nec-1 ~ 5-fold, with an additive effect with a combination of the inhibitors ~7-fold ( Figure S2A,B) . The addition of wtTNF did not induce an additive effect. These data imply that TNFR2 and STAT3 signals are important in sustaining cell viability and that their absence induces cell death predominantly via a caspase-independent pathway in ccRCC-
CSCs, consistent with our previous report. Figure S6A ,B) and cell death but significantly less (~2-fold) compared to that observed in ccRCC-CD133+ CSCs (Table S1 ). Ligation of TNFR2 also induces the mitochondrial translocation of TNFR2 and STAT3 in NK-CD133+ cells ( Figure S6C ). Percentage represents mean ± SEM, n = 3 samples and each treatment group.
Abbreviations: n, necrostatin-1 (30 μmol/L); NTsiRNA, nontargeting siRNA; R1TNF and R2TNF, wtTNF mutein selectively binds to TNFR1 or TNFR2 -1 μg/mL; STAT3siRNA, siRNA targeting STAT3; TNFR2siRNA, siRNA targeting TNFR2; UT, Untreated (in media alone), T-Wild-type (wt)TNF (10 ng/mL); z, z-VAD.fmk (20 μmol/L) of STAT3 in NK-CD133+ cells, but the propensity of these cells to undergo mitochondrial-mediated necroptosis is significantly reduced and inhibiting this response results in less cell death.
| DISCUSSION
We previously reported that ligation of TNFR2 drives ccRCC-
CD133+
CSCs proliferation and increases their sensitivity to cell cycle-dependent cytotoxicity. 21 Here we elucidate the mechanism of the growth-promoting effect of TNFR2 signaling in CD133 + CSCs in ccRCC using molecular, cellular, and imaging techniques. We demonstrate various important findings: (a) TNF rapidly induces (within 30 minutes) pSTAT3 Although outcomes for patients with advanced RCC have improved in recent years with the development of targeted therapies, curative treatment remains elusive. The putative anti-tumor activity of infliximab (anti-TNF antibody) was demonstrated in advanced RCC, 42 but a subsequent phase I/II trial using a combination of infliximab and the multi-kinase inhibitor sorafenib showed adverse events with lack of efficacy. 43 Our data indicate that blocking TNFR2 may account Percentage represents mean ± SEM, n = 3 samples and each treatment group.
Abbreviations: NAC, N-Acetyl Cysteine (anti-oxidant-250 mmol/L); NTsiRNA, nontargeting siRNA; R1TNF and R2TNF, wtTNF mutein selectively binds to TNFR1 or TNFR2 -1 μg/mL; STAT3siRNA, siRNA targeting STAT3; TNFR2siRNA, siRNA targeting TNFR2; UT, Untreated (in media alone); T-Wild-type (wt)TNF (10 ng/mL).
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for adverse outcomes and suggest that a TNFR2 agonist combined with standard chemotherapy regimens may offer greater efficacy. Within the tumor microenvironment, a complex network of signals affects tumor initiation and progression. TNF is a putative autocrine and paracrine growth factor in RCC 3, 44 and increases stemness via the induction of epithelial-mesenchymal transition. 45 Ser727 involves the activation of VEGFR2/ PI-3K/Akt/mTORC1/2 pathway in ccRCC-CD133+ CSCs. As predicted, specific inhibitors of this pathway resulted in increased cell death, implicating them in the TNFR2/STAT3-mediated survival pathway. The involvement of VEGFR2 in TNFR2 signaling is consistent with our previous report 3 and further implicates the phosphorylation of VEGFR2 in TNFR2-mediated survival. The PI-3K/Akt/mTOR pathway regulates cell survival in a variety of tumor types including RCC and aberrant hyperactivation is a target for cancer therapy. 51 An association between suppression of PI-3K/Akt/mTORC pathway and STAT3 on inhibition of cell proliferation has been reported. 52 Collectively, our data suggest a close connection between TNFR2/pSTAT3 Ser727 signaling and VEGFR2/PI-3K/Akt/mTORC pathways in driving survival of ccRCC-CD133 + CSCs. These findings may explain why therapy directed against these kinases have provided only modest survival benefits. 53 Moreover, clinical therapy involving adjuvant trial with receptor tyrosine kinases in RCC has also reported no improvement in disease-free survival and patients have experienced adverse events. 54 The importance of these kinases in driving the survival of CSCs via TNFR2 signaling and the ability of TNFR2 to sensitize CSCs to cytotoxic killing strongly suggest that a therapeutic strategy for the eradication of ccRCC would be cytotoxics in the absence of VEGFR2/PI-3K/Akt/mTOR inhibition. However, further studies will be required to determine whether these kinases act in a cascade in response to TNFR2 signaling. Our data showing TNFR2-mediated mitochondrial expression of TNFR2 and its association with pSTAT3 Ser727 implicate mitochondria in the survival pathway. Our EM data showing disrupted mitochondrial morphology in the absence of TNFR2/STAT3 signals further supports our line of thought. Previous studies have shown TNFR2 to confer mitochondria-dependent cardioprotective effects via STAT3 activation. 55 We identified a TNF-binding protein in the inner mitochondrial membrane that can be detected by a monoclonal antibody to TNFR2. 6 The mechanism by which TNFR2 is recruited to the mitochondria is unclear. It may require an adaptor protein such as E3 ubiquitin ligase TRAF2 (TNF receptor-associated factor-2), which plays a key pro-survival role as an adaptor protein to transduce the activation of kinases and transcription factors. 56 Studies using rat pancreatic insulin-producing INS-1E beta cell lines have reported that TRAF2 is required for the IFNγ-stimulated phosphorylation of STAT3 and that TRAF2 knockdown increases the cytokine-induced production of ROS. 57 An earlier report has detected the TNF-induction of TRAF2 expression in mitochondria of RCC-26 by immunoblotting. 58 Thus, TRAF2 may be an important mediator of mitochondrial TNFR2/pSTAT3 Ser727 signaling. Another member of the TNFR2 signaling complex associated with mitochondria is aminopeptidase P3 (APP3). 59 Further studies will be required to determine the role of TNFR2 in mediating pSTAT3 Ser727 localization in mitochondria and the role of TRAF2 and APP3 in TNFR2/STAT3 signaling in ccRCC-CD133+ CSCs. Alternatively, pSTAT3
Ser727 may mediate its mitochondrial translocation. 60 Indeed, STAT3 can act as a positive or negative regulator of mitochondrial activity depending on specific modifications. 61 
Mitochondrial pSTAT3
Ser727 has been shown to be important in the growth/survival of cancer and its function is distinct from nuclear transcriptional regulation. Using siRNA knockdown, we observed a dramatic increase in cell death with the absence of TNFR2/STAT3 signals altering mitochondrial morphology with the loss of cristae and outer membrane disruption, associated with cytosolic release of cytochrome c, generation of ROS, caspase-3 cleavage, and MLKL phosphorylation. The specific mechanism of mitochondria in the induction of cell death in this context is unclear, but may involve ROS modulator 1 (Romo1) recruitment of B-cell lymphoma-extralarge (Bcl-X(L). 64 Whatever the mechanism, these data support a central role for mitochondria in TNFR2/STAT3 signaling. Additionally, increased expression of pMLK-L Ser358 and attenuation of cell death by Nec-1 as compared to z-VAD.fmk strongly indicates the dominance of caspase-independent cell death (necroptosis), consistent with our previous report. 2 Maintenance of normal mitochondrial morphology has been shown to regulate several aspects of mitochondrial functioning, including mitochondrial metabolism, ROS production, and induction of apoptosis. 65 Mitochondrial involvement in cell death involved cytochrome c release and combination with cytosolic apoptotic protease activating factor (APAF)-1 and, in the presence of ATP, the formation of a complex that binds and promotes autocatalytic activation of the initiator caspase 9. Activated caspase 9 proteolytically activates executioner caspases including caspase-3 resulting in apoptosis. Other released proteins, including second mitochondrial activator of cell death (SMAC)/Diablo, which augments caspase activation, or apoptosis inducing factor (AIF), may also trigger death. 66 AIF is misnamed because, unlike cytochrome c and SMAC/Diablo, it acts independently of caspases 66 and death may result from events triggered following its nuclear translocation and dysregulated mitochondrial function. Importantly, we show that blocking TNFR1 signals confers only partial protection from cell death induced by the absence of TNFR2/STAT3 signals, suggesting the involvement of an unknown mechanism, perhaps similar to that reported by Lacerda et al, where TNF's effect on mitochondria is independent of its cell surface receptors and , and generation of ROS, which can be blocked by NAC. Cell death is partially inhibited by z-VAD.fmk, further attenuated by Nec-1, with an additive effect by a combination of both z-VAD.fmk and Nec-1, indicating the dominance of necroptotic cell death pathway occur via ROS generation. 50 Unexpectedly, the absence of TNFR1 signals alone induced cytotoxic effect, albeit small compared to that induced by the absence of TNFR2/STAT3 signals either alone or in combination. wtTNF or R1TNF did not significantly attenuate cell death induced by the absence of TNFR2/STAT3 signals in ccRCC-CD133+ CSCs, indicating that they do not confer an additive effect. These data point to an essential role for TNFR2/STAT3 signaling in the survival of CSCs independent of TNFR1 signals. Although TNFR2 is regarded to have exclusively pro-survival functions, whereas TNFR1 signals cell death, 2 emerging evidence indicates some overlap in TNFR2 and TNFR1-induced functions. Both TNF receptors are capable of mediating similar functions under certain circumstances, including cell death, proliferation, differentiation, and cytokine production. 67 Various factors including cell type, cell activation state, intracellular or extracellular environment, and whether nuclear factor kappa-B is constitutively expressed, may lead to a degree of functional overlap. 67 In summary, we propose the model shown in Figure , and generation of ROS. Cell death is partially inhibited by z-VAD.fmk, further attenuated by Nec-1, with an additive effect of a combination of both z-VAD.fmk and Nec-1, indicating the dominance of necroptotic cell death.
The reported insensitivity of CSCs to chemotherapy and radiotherapy 68 suggests that current anti-cancer drugs, which inhibit tumor cells, may not effectively inhibit CSCs. The clinical relevance of targeting CSCs is supported by recent studies, including CD24 targeting for the treatment of pancreatic and colon, 69 CD44 targeting for the treatment of acute myeloid leukemia 70 and CD133 targeting for gastric and hepatocellular cancer. 71 In conclusion, our data here and from our previous studies 21 indicate that an alternative therapeutic strategy for eradication of ccRCC would be to promote CSCs survival by a TNFR2 selective agonist in combination with cell-cycle dependent cytotoxic drugs. Importantly, mechanistic differences between normal stem cells and cancer stem cells could be targeted to deplete CSCs without damaging normal stem cells.
